CTSHIV: a knowledge-based system for the management of HIV-infected patients

A rule based expert system, CTSHIV (Customized Treatment Strategies for HIV) that recommends an individualized treatment strategy for HIV patients is described. Since the HIV virus mutates rapidly, a patient can develop a resistance to particular antiretroviral agents. CTSHIV addresses this problem by recommending a treatment strategy that avoids antiretroviral agents for which a resistance has developed. By monitoring the HIV virus of the patient, the treatment strategy can be switched in response to mutations of the virus. CTSHIV contains a knowledge base that encodes information from the medical literature on drug resistant mutations. It also contains additional rules that rank and weight combinations of antiretroviral agents based upon antiviral activities, redundant mechanisms of action, and overlapping toxicities. To recommend a treatment for an HIV infected patient, plasma is obtained from the patient and the RNA extracted. Segments of the HIV pol gene encoding the entire protease, reverse transcriptase and integrase proteins are amplified by RT-PCR (using a total of 3 primer pairs) and cloned. The patient's HIV sequencing data is entered into the expert program and the information is downloaded directly into the CTSHIV program. The program produces the five most effective 2, 3, and 4 drug regimens coupled with an explanation for their choice. Thus, the CTSHIV system couples efficient genetic sequencing with an expert program that recommends regimens based upon information in the current medical literature. Clinical trials are underway to evaluate the effectiveness of this approach to the management of HIV infected patients.

[1]  E. De Clercq,et al.  Antiviral therapy for human immunodeficiency virus infections , 1995, Clinical microbiology reviews.

[2]  J W Mulder,et al.  Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. , 1996, The Journal of infectious diseases.

[3]  Peter Jackson,et al.  Introduction to expert systems , 1986 .

[4]  D. Richman,et al.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Katzenstein,et al.  Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. , 1993, Journal of acquired immune deficiency syndromes.

[6]  S D Kemp,et al.  Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture , 1991, Journal of virology.

[7]  S D Kemp,et al.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.

[8]  S D Kemp,et al.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. , 1991, AIDS.

[9]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[10]  S. Dewhurst,et al.  Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine , 1995, Journal of clinical microbiology.

[11]  T. Chou,et al.  Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. , 1996, AIDS research and human retroviruses.

[12]  S W Tu,et al.  AIDS2: a decision-support tool for decreasing physicians' uncertainty regarding patient eligibility for HIV treatment protocols. , 1993, Proceedings. Symposium on Computer Applications in Medical Care.

[13]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[14]  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1990, Disease markers.

[15]  M A Wainberg,et al.  Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. , 1994, Leukemia.

[16]  M A Wainberg,et al.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine , 1992, Journal of virology.

[17]  T. Merigan,et al.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[18]  J. Lange,et al.  Triple combinations: present and future. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  S. Frost,et al.  Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection , 1994, AIDS.